The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

High-Concentration Version of Adalimumab Biosimilar Will Be Available in 2023

August 23rd 2022, 4:00pm


The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already approved. Both versions will launch in July 2023.

How Health Care Institutions Can Leverage Biosimilars to Generate Savings

August 17th 2022, 5:00pm


On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.

Can Reassurance Techniques Improve Patient Confidence in Biosimilars for Psoriasis?

August 13th 2022, 3:20pm


A number of psychologic interventions were assessed to see if they could have an effect on patient confidence in biosimilars to treat psoriasis.

2023 Biosimilars Landscape

August 12th 2022, 3:47pm


Drs Oskouei and Alboustani discuss implications of multiple biosimilars for adalimumab and how indications are extrapolated for a biosimilar.

Biosimilar and Interchangeable Biosimilar Conversion Programs

August 12th 2022, 3:39pm


Drs Atheer Kaddis and Mariam Alboustani delve into biosimilar conversion programs, including switching policies for interchangeability.

Bevacizumab Biosimilar Comparable to Reference Across Disease States

August 10th 2022, 9:15pm


The single-center study evaluated patients across multiple cancers to understand the utilization, safety, and financial outcomes of bevacizumab-awwb vs reference bevavizumab.

Automatic Substitution With Interchangeable Biosimilars

August 5th 2022, 12:43pm


Dr Sonia T. Oskouei focuses on automatic substitution in both the pharmacy setting and in patients’ health plans.

Looking at Published Data and Implications of Interchangeability

August 5th 2022, 12:38pm


Mariam Alboustani, PharmD, discusses the one published example of a switching study and the implications of interchangeability for pharmacists, as well as payers.

Data Support Safety, Effectiveness of Biosimilar-to-Biosimilar Switching

August 3rd 2022, 3:47pm


Although there is a paucity of data of switching among biosimilars of the same reference product, the few studies published support the safety and effectiveness of transitioning patients from one biosimilar to another.

Defining Interchangeable Biosimilars

July 29th 2022, 6:26pm


Drs Kaddis and Oskouei define interchangeable biosimilars, their FDA requirements, and switching studies.